CooperSurgical Acquisitions show how a medical and surgical products company used mergers and acquisitions to expand across women’s health, reproductive medicine, fertility, gynecology, obstetrics, genetic testing, single-use surgical devices, fetal monitoring, and medical device manufacturing.
Between 2000 and 2024, CooperSurgical made 14 acquisitions with a total disclosed deal value of about $1.5 billion. The average disclosed deal size was approximately $108.8 million, although that figure was heavily shaped by the $875.0 million acquisition of Cook Medical’s Reproductive Health Portfolio in 2022.
The company’s M&A activity focused entirely on health care, with 14 deals. Medical device companies accounted for 8 deals, while manufacturing appeared in 6 deals. Biotechnology accounted for 4 deals, and fertility appeared in 1 listed category. This pattern fits CooperSurgical’s role as a provider of a full portfolio of medical and surgical products, especially in women’s health.
The most recent listed acquisition was obp Surgical, acquired in August 2024 for $100.0 million. The company develops single-use surgical devices, including ONETRAC, designed to improve safety and efficiency in surgery.
What Is CooperSurgical?
CooperSurgical provides a full portfolio of medical and surgical products. Its acquisition history shows a strong focus on women’s health, reproductive health, fertility, obstetrics, gynecology, surgical instruments, genetic testing, and medical devices.
The company’s targets have included fetal and vascular ultrasound systems, obstetric and gynecological disposable products, female sterilization devices, pessaries, surgical instruments, hysteroscopy devices, reproductive genetics laboratories, micromanipulation systems, reproductive health portfolios, and single-use surgical devices.
That makes CooperSurgical’s acquisition strategy highly focused. Unlike diversified healthcare companies that buy across pharmaceuticals, hospitals, software, and insurance, CooperSurgical’s listed deals stayed close to clinical specialties where medical devices and reproductive health tools matter.
The result is a portfolio built around practical clinical use: helping physicians diagnose, treat, monitor, test, and perform procedures in women’s health and reproductive medicine.
Why CooperSurgical Acquisitions Matter
CooperSurgical Acquisitions matter because women’s health and fertility care depend on specialized tools, devices, laboratory services, and clinical products.
A gynecology practice may need diagnostic instruments, hysteroscopy tools, pessaries, sterilization devices, disposable products, and surgical devices. A fertility clinic may need embryo testing, micromanipulation systems, reproductive health devices, and laboratory support. Obstetric care may require fetal monitoring and related diagnostic products.
Acquisitions helped CooperSurgical expand across those needs.
First, the company built an early base in obstetrics and gynecology devices through Medasonics, Prism Enterprises, Avalon Medical, Milex Products, Lone Star Medical Products, and Wallach Surgical Devices.
Second, CooperSurgical expanded into fertility and reproductive genetics through Reprogenetics, Research Instruments, Genesis Genetics, and Cook Medical’s Reproductive Health Portfolio.
Third, it strengthened surgical access and device efficiency through Endosee, OBP Medical, Smiths Medical, and obp Surgical.
Fourth, the company used M&A to add manufacturing capabilities. Several targets designed, manufactured, or marketed medical devices, allowing CooperSurgical to deepen its product portfolio and clinical reach.
The overall pattern shows a company using targeted acquisitions to build a more complete women’s health and reproductive medicine platform.
Full List of CooperSurgical Acquisitions
| Acquiree | Announced Date | Price | Main Category | Strategic Value |
|---|---|---|---|---|
| obp Surgical | Aug 1, 2024 | $100.0M | Health Care | Added single-use surgical devices, including ONETRAC, designed to improve surgical safety and efficiency. |
| Cook Medical – Reproductive Health Portfolio | Feb 7, 2022 | $875.0M | Fertility | Added fertility, gynecology, and fertilization medical device manufacturing capabilities. |
| OBP Medical | May 3, 2021 | $60.0M | Medical Device | Added single-use medical device solutions. |
| Smiths Medical | Nov 7, 2016 | $174.0M | Medical Device | Added specialized medical technologies focused on delivery, vital care, and safety devices. |
| Genesis Genetics | Apr 4, 2016 | $60.0M | Biotechnology | Added pre-implantation embryo testing for inherited genetic abnormalities. |
| Research Instruments | Dec 17, 2015 | $51.0M | Biotechnology | Added micromanipulation systems for reproductive and laboratory applications. |
| Reprogenetics | Aug 10, 2015 | $46.5M | Biotechnology | Added preimplantation genetic screening and diagnosis laboratory capability. |
| Endosee | Oct 9, 2014 | $44.0M | Medical Device | Added office hysteroscopy instruments. |
| Wallach Surgical Devices | Feb 22, 2007 | $20.0M | Medical Device | Added diagnostic and therapeutic products for obstetrics. |
| Lone Star Medical Products | Nov 2, 2006 | $27.2M | Medical Device | Added medical device design, manufacturing, and marketing capability. |
| Milex Products | Feb 3, 2004 | $26.0M | Health Care | Added pessaries for uterine prolapse, urinary stress incontinence, rectocele, and cystocele. |
| Avalon Medical corp. | Oct 28, 2003 | $10.0M | Medical Device | Added distribution of the Filshie Clip System for female sterilization. |
| Prism Enterprises | May 5, 2003 | $23.0M | Medical Device | Added obstetric and gynecological medical devices and disposable products. |
| Medasonics | Oct 18, 2000 | $7.1M | Health Care | Added fetal and vascular handheld Doppler ultrasound systems. |
CooperSurgical Acquisitions Timeline
2000: Fetal and Vascular Ultrasound Through Medasonics
CooperSurgical’s listed acquisition history begins in 2000 with Medasonics, acquired for $7.1 million. Medasonics manufactured and marketed fetal and vascular handheld Doppler ultrasound systems.
This deal fit CooperSurgical’s women’s health focus. Fetal monitoring and vascular assessment tools are practical clinical products used in medical settings where reliable diagnostic information matters.
The acquisition gave CooperSurgical an early device capability tied to obstetric and clinical monitoring.
2003: Obstetric, Gynecological, and Female Sterilization Products
In 2003, CooperSurgical acquired Prism Enterprises and Avalon Medical.
Prism Enterprises, acquired for $23.0 million, developed, manufactured, and sold medical devices and disposable products for obstetric and gynecological markets. Avalon Medical, acquired for $10.0 million, distributed the Filshie Clip System, a device used for female sterilization.
These acquisitions strengthened CooperSurgical’s position in women’s health procedures. They also show the company adding products used directly by clinicians in obstetric, gynecological, and reproductive care.
2004: Pelvic Support Products Through Milex
In 2004, CooperSurgical acquired Milex Products for $26.0 million. Milex offered pessaries for uterine prolapse, urinary stress incontinence, rectocele, and cystocele.
This acquisition expanded CooperSurgical into pelvic health and gynecological support products. Pessaries serve an important clinical need for patients dealing with pelvic organ prolapse and related conditions.
The deal also added a recurring women’s health product category that fits closely with gynecology practices.
2006: Medical Device Manufacturing Through Lone Star
In 2006, CooperSurgical acquired Lone Star Medical Products for $27.2 million. Lone Star designed, manufactured, and marketed medical devices.
The acquisition strengthened CooperSurgical’s medical device manufacturing base. For a surgical products company, in-house or portfolio-level device manufacturing capability can improve product depth and clinical reach.
2007: Obstetric Diagnostic and Therapeutic Products
In 2007, CooperSurgical acquired Wallach Surgical Devices for $20.0 million. Wallach designed and manufactured diagnostic and therapeutic products for obstetrics.
This deal continued the company’s focus on women’s health devices. Obstetric diagnostics and therapeutic tools are central to clinical care, making Wallach a logical fit for CooperSurgical’s portfolio.
2014: Office Hysteroscopy Through Endosee
In 2014, CooperSurgical acquired Endosee for $44.0 million. Endosee developed instruments for office hysteroscopy.
Hysteroscopy is important in gynecology because it allows clinicians to examine the inside of the uterus. Office-based instruments can improve convenience and support care delivery outside more complex procedural settings.
This acquisition strengthened CooperSurgical’s gynecological device portfolio.
2015: Reproductive Genetics and Micromanipulation Systems
In 2015, CooperSurgical acquired Reprogenetics and Research Instruments.
Reprogenetics, acquired for $46.5 million, was a genetics laboratory focused on preimplantation genetic screening and preimplantation diagnosis. Research Instruments, acquired for $51.0 million, developed micromanipulation systems.
These deals marked a deeper move into fertility and reproductive medicine. Genetic screening, embryo testing, and micromanipulation systems are important in assisted reproduction and fertility laboratory workflows.
2016: Genetic Testing and Specialized Medical Technologies
In 2016, CooperSurgical acquired Genesis Genetics and Smiths Medical.
Genesis Genetics, acquired for $60.0 million, provided pre-implantation testing of embryos for inherited genetic abnormalities. Smiths Medical, acquired for $174.0 million, provided specialized medical technologies focused on delivery, vital care, and safety devices.
Genesis Genetics reinforced CooperSurgical’s reproductive genetics platform. Smiths Medical added broader medical technology exposure, especially around delivery, vital care, and safety devices.
2021: Single-Use Device Solutions Through OBP Medical
In 2021, CooperSurgical acquired OBP Medical for $60.0 million. OBP Medical developed single-use device solutions for medical devices.
This acquisition strengthened CooperSurgical’s single-use device capabilities. Single-use devices can improve convenience, reduce reprocessing needs, and support safety in clinical environments.
2022: Reproductive Health Scale Through Cook Medical Portfolio
In 2022, CooperSurgical acquired Cook Medical’s Reproductive Health Portfolio for $875.0 million. The portfolio manufactured medical devices for fertility, gynecology, and fertilization.
This was the largest listed CooperSurgical acquisition by a wide margin. It significantly expanded the company’s reproductive health platform and deepened its presence in fertility-related medical devices.
The acquisition also reinforced CooperSurgical’s position in women’s health, where fertility, gynecology, and reproductive medicine are central themes.
2024: Surgical Efficiency Through obp Surgical
In 2024, CooperSurgical acquired obp Surgical for $100.0 million. obp Surgical developed single-use surgical devices such as ONETRAC, designed to improve safety and efficiency in surgery.
This was the most recent listed acquisition. It continued CooperSurgical’s focus on medical devices and single-use surgical tools.
The deal also showed the company strengthening surgical workflow and device efficiency, a practical theme across medical device markets.
Biggest CooperSurgical Acquisitions by Deal Value
| Rank | Acquiree | Announced Date | Price | Strategic Theme |
|---|---|---|---|---|
| 1 | Cook Medical – Reproductive Health Portfolio | Feb 7, 2022 | $875.0M | Fertility, gynecology, and fertilization devices |
| 2 | Smiths Medical | Nov 7, 2016 | $174.0M | Delivery, vital care, and safety devices |
| 3 | obp Surgical | Aug 1, 2024 | $100.0M | Single-use surgical devices |
| 4 | OBP Medical | May 3, 2021 | $60.0M | Single-use medical device solutions |
| 5 | Genesis Genetics | Apr 4, 2016 | $60.0M | Pre-implantation embryo testing |
| 6 | Research Instruments | Dec 17, 2015 | $51.0M | Micromanipulation systems |
| 7 | Reprogenetics | Aug 10, 2015 | $46.5M | Preimplantation genetic screening and diagnosis |
| 8 | Endosee | Oct 9, 2014 | $44.0M | Office hysteroscopy instruments |
| 9 | Lone Star Medical Products | Nov 2, 2006 | $27.2M | Medical device design and manufacturing |
| 10 | Milex Products | Feb 3, 2004 | $26.0M | Pessaries and pelvic support products |
The ranking shows that CooperSurgical’s acquisition strategy was dominated financially by Cook Medical’s Reproductive Health Portfolio. However, several smaller and mid-sized deals also shaped the company’s platform in reproductive genetics, surgical devices, obstetrics, gynecology, and single-use medical products.
Most Common Acquisition Categories
| Category | Number of Deals | What It Suggests |
|---|---|---|
| Health Care | 14 | Every listed CooperSurgical acquisition was tied to health care. |
| Medical Device | 8 | The company repeatedly targeted device makers and surgical product businesses. |
| Manufacturing | 6 | CooperSurgical added product design, production, and manufacturing capability. |
| Biotechnology | 4 | Reproductive genetics and embryo testing were important themes. |
| Fertility | 1 | The Cook Medical reproductive health portfolio strengthened fertility-related devices. |
This category mix confirms that CooperSurgical Acquisitions were highly focused. The company used M&A to build depth in women’s health and medical devices rather than diversify into unrelated markets.
Strategic Lessons From CooperSurgical Acquisitions
Women’s Health Was the Central Theme
Most acquisitions served women’s health, obstetrics, gynecology, fertility, or reproductive medicine. That focus gave CooperSurgical a clear strategic identity.
In M&A, focus matters. CooperSurgical’s acquisition history shows a company building around clinical specialization rather than broad healthcare diversification.
Fertility Became a Major Growth Area
Reprogenetics, Research Instruments, Genesis Genetics, and Cook Medical’s Reproductive Health Portfolio all strengthened fertility and reproductive medicine.
These deals show CooperSurgical moving beyond traditional surgical products into laboratory, genetics, and assisted reproduction support.
Single-Use Devices Became More Important
OBP Medical and obp Surgical both focused on single-use device solutions. This reflects demand for devices that can support efficiency, safety, and convenience in clinical settings.
Manufacturing Capability Supported Portfolio Control
Six acquisitions were tied to manufacturing. That matters because medical device companies need product reliability, quality control, regulatory compliance, and consistent supply.
How CooperSurgical Acquisitions Fit Its Business Model
CooperSurgical’s business model centers on medical and surgical products, especially those used in women’s health and reproductive care. Acquisitions fit that model because the company can build a broader product portfolio for clinicians, fertility clinics, hospitals, and surgical settings.
A gynecologist may need hysteroscopy instruments, pessaries, diagnostic tools, and surgical devices. A fertility clinic may need embryo testing, micromanipulation systems, and reproductive health devices. A surgical team may benefit from single-use devices designed to improve efficiency and safety.
CooperSurgical’s acquisitions added products and capabilities across these workflows. That gives the company more ways to serve the same customer base while deepening its relevance in specialized care settings.
Financial and Ownership Context
CooperSurgical made 14 acquisitions from 2000 to 2024, with total disclosed deal value of about $1.5 billion. The average disclosed deal size was approximately $108.8 million.
The largest acquisition was Cook Medical’s Reproductive Health Portfolio at $875.0 million. That transaction accounted for a major share of total disclosed value. Smiths Medical followed at $174.0 million, while obp Surgical was acquired for $100.0 million.
Most other listed deals were smaller, ranging from $7.1 million for Medasonics to $60.0 million for OBP Medical and Genesis Genetics.
This financial pattern suggests a strategy built on targeted acquisitions, with one large platform deal in reproductive health. For analysts, the main question is whether these acquisitions strengthened CooperSurgical’s position in women’s health, fertility, and medical devices.
Competitive Impact of CooperSurgical Acquisitions
CooperSurgical competes in specialized medical device and women’s health markets. Its acquisitions improved competitive positioning in several ways.
In obstetrics and gynecology, Medasonics, Prism Enterprises, Avalon Medical, Milex Products, Wallach Surgical Devices, and Endosee expanded the product base.
In fertility and reproductive medicine, Reprogenetics, Research Instruments, Genesis Genetics, and Cook Medical’s Reproductive Health Portfolio deepened clinical and laboratory capabilities.
In single-use devices, OBP Medical and obp Surgical added products designed for procedural efficiency and safety.
This breadth can make CooperSurgical more important to clinicians and fertility providers. A broader product portfolio may also support stronger sales relationships and cross-selling opportunities.
However, the company operates in regulated medical markets. Product quality, safety, clinical effectiveness, manufacturing reliability, and compliance remain critical.
Advantages of the Acquisition Strategy
Clear Focus on Women’s Health
CooperSurgical’s acquisition strategy stayed closely tied to women’s health, fertility, gynecology, obstetrics, and reproductive medicine.
Broader Medical Device Portfolio
The company added diagnostic, therapeutic, surgical, single-use, and reproductive health devices.
Stronger Fertility Platform
Acquisitions in embryo testing, genetic screening, micromanipulation systems, and reproductive health devices strengthened fertility care exposure.
Manufacturing and Product Control
Several acquisitions added design, manufacturing, and marketing capabilities for medical devices.
Deeper Clinical Relevance
The acquired products serve real clinical workflows, from fetal monitoring and hysteroscopy to embryo testing and surgical device use.
Disadvantages of the Acquisition Strategy
Regulatory Risk
Medical devices, fertility products, genetic testing, and surgical tools operate in regulated markets. Compliance failures can create serious risk.
Integration Complexity
CooperSurgical acquired device companies, laboratories, manufacturing businesses, and product portfolios. Integrating them requires operational discipline.
Dependence on Specialist Markets
A strong focus on women’s health can create strategic clarity, but it also concentrates exposure in specific clinical categories.
Quality and Safety Expectations
Medical and surgical products must meet high quality and safety standards. Any product issue can damage trust.
Large Deal Execution Risk
The Cook Medical Reproductive Health Portfolio acquisition was much larger than most other listed deals, making successful integration especially important.
Case Studies of Major CooperSurgical Acquisitions
Cook Medical – Reproductive Health Portfolio
Cook Medical’s Reproductive Health Portfolio was acquired for $875.0 million in 2022. The portfolio manufactured medical devices for fertility, gynecology, and fertilization.
This was the largest listed CooperSurgical acquisition. It significantly expanded the company’s reproductive health device platform and strengthened its position in fertility and gynecology.
The deal was strategically important because it aligned directly with CooperSurgical’s core women’s health focus.
Smiths Medical
Smiths Medical was acquired for $174.0 million in 2016. It provided specialized medical technologies focused on delivery, vital care, and safety devices.
This acquisition added broader medical technology exposure and strengthened CooperSurgical’s medical device portfolio.
obp Surgical
obp Surgical was acquired for $100.0 million in 2024. It develops single-use surgical devices such as ONETRAC.
The acquisition strengthened CooperSurgical’s single-use surgical device capabilities and reflected demand for products that improve procedural safety and efficiency.
Genesis Genetics
Genesis Genetics was acquired for $60.0 million in 2016. It provided pre-implantation embryo testing for inherited genetic abnormalities.
This acquisition expanded CooperSurgical’s reproductive genetics capability and supported fertility clinic workflows.
Research Instruments
Research Instruments was acquired for $51.0 million in 2015. It developed micromanipulation systems.
This acquisition added important laboratory technology for reproductive medicine and fertility applications.
Common Mistakes When Analyzing CooperSurgical Acquisitions
One common mistake is treating CooperSurgical as a broad healthcare acquirer. Its acquisition record is much more focused on women’s health, fertility, gynecology, obstetrics, and medical devices.
Another mistake is focusing only on the Cook Medical deal. It was the largest acquisition, but smaller deals such as Reprogenetics, Genesis Genetics, Endosee, Milex, and OBP Medical also shaped the strategy.
A third mistake is overlooking reproductive genetics. Preimplantation testing and embryo screening were important themes in the company’s acquisition history.
Another mistake is assuming single-use surgical devices are minor add-ons. OBP Medical and obp Surgical show that single-use device solutions became a meaningful strategic theme.
Analysts should also avoid ignoring regulatory and quality requirements. In medical devices, acquisition success depends on safety, compliance, manufacturing standards, and clinician trust.
Lessons for Business Owners and Investors
CooperSurgical’s acquisition history offers several lessons.
The first lesson is that focused M&A can build a strong specialist platform. CooperSurgical stayed close to women’s health and reproductive medicine.
The second lesson is that fertility markets require both devices and laboratory capabilities. The company acquired reproductive genetics, micromanipulation systems, and reproductive health devices.
The third lesson is that small medical device deals can add valuable clinical products.
The fourth lesson is that product quality and regulatory compliance matter as much as strategy.
The fifth lesson is that a single large platform acquisition can reshape a company’s portfolio, as seen with Cook Medical’s Reproductive Health Portfolio.
Key Takeaways
- CooperSurgical made 14 acquisitions between 2000 and 2024.
- Total disclosed deal value across CooperSurgical Acquisitions is about $1.5 billion.
- The average disclosed acquisition size is approximately $108.8 million.
- Health care accounted for all 14 listed acquisitions.
- Medical device companies accounted for 8 deals.
- Manufacturing appeared in 6 deals.
- Biotechnology accounted for 4 deals.
- Cook Medical’s Reproductive Health Portfolio was the largest acquisition at $875.0 million.
- obp Surgical was the most recent listed acquisition, announced in 2024 for $100.0 million.
- CooperSurgical used M&A to expand in women’s health, fertility, gynecology, obstetrics, genetic testing, surgical devices, and single-use medical products.
- Key risks include regulation, quality control, integration complexity, specialist market concentration, and large-deal execution.
Frequently Asked Questions
What are CooperSurgical Acquisitions?
CooperSurgical Acquisitions are companies and product portfolios acquired by CooperSurgical to expand its women’s health, fertility, gynecology, obstetrics, medical device, genetic testing, and surgical product capabilities.
How many acquisitions has CooperSurgical made?
CooperSurgical made 14 listed acquisitions spanning from 2000 to 2024.
What is the total value of CooperSurgical acquisitions?
The total disclosed value of CooperSurgical acquisitions is about $1.5 billion.
What is CooperSurgical’s average acquisition size?
CooperSurgical’s average disclosed acquisition size is approximately $108.8 million.
What was CooperSurgical’s most recent acquisition?
The most recent listed acquisition was obp Surgical, announced on August 1, 2024, for $100.0 million.
What is CooperSurgical’s biggest acquisition?
The biggest listed acquisition was Cook Medical’s Reproductive Health Portfolio, acquired in 2022 for $875.0 million.
Which sectors does CooperSurgical acquire most often?
CooperSurgical most often acquires companies in health care, medical devices, manufacturing, biotechnology, and fertility.
Why did CooperSurgical acquire Cook Medical’s Reproductive Health Portfolio?
CooperSurgical acquired Cook Medical’s Reproductive Health Portfolio to expand its fertility, gynecology, and fertilization medical device platform.
Why are reproductive genetics acquisitions important to CooperSurgical?
Reproductive genetics acquisitions such as Reprogenetics and Genesis Genetics strengthened CooperSurgical’s fertility and embryo testing capabilities.
Are CooperSurgical acquisitions mainly women’s health deals?
Yes. The acquisition record is strongly focused on women’s health, reproductive medicine, obstetrics, gynecology, fertility, and related medical devices.
What are the main risks of CooperSurgical’s acquisition strategy?
The main risks include regulatory compliance, product quality, integration complexity, safety expectations, specialist market concentration, and execution risk on large acquisitions.
Do CooperSurgical acquisitions guarantee growth?
No. Acquisitions can support growth, but success depends on integration, clinician adoption, product quality, regulatory compliance, manufacturing reliability, and market demand.
Conclusion
CooperSurgical Acquisitions show how a medical and surgical products company used M&A to build a focused platform in women’s health, fertility, gynecology, obstetrics, reproductive genetics, single-use surgical devices, and medical device manufacturing.
The company made 14 listed acquisitions from 2000 to 2024, with total disclosed deal value of about $1.5 billion and an average disclosed acquisition size of approximately $108.8 million. Its largest listed acquisition was Cook Medical’s Reproductive Health Portfolio at $875.0 million, while its most recent listed acquisition was obp Surgical at $100.0 million.
The pattern is clear. CooperSurgical did not pursue broad, unrelated healthcare diversification. It acquired companies that fit clinical workflows in women’s health and reproductive medicine. Deals such as Medasonics, Prism Enterprises, Milex Products, Endosee, Reprogenetics, Research Instruments, Genesis Genetics, OBP Medical, Cook Medical’s Reproductive Health Portfolio, and obp Surgical all support that strategy.
At the same time, medical device M&A carries real risks. Regulatory compliance, product quality, clinical adoption, manufacturing standards, and integration discipline all determine whether acquisitions create long-term value.
For business owners, investors, and healthcare analysts, CooperSurgical offers a focused case study in acquisition-led medical device expansion. CooperSurgical Acquisitions show how targeted M&A can help a healthcare company deepen its specialist position in women’s health and fertility care.
Disclaimer: This article is for informational and educational purposes only. It is not investment advice, financial advice, or a recommendation to buy or sell any security. Always conduct your own research and consider speaking with a qualified financial adviser before making investment decisions.
Read Also: Connection Capital Acquisitions: How Connection Capital Built Its Business Through M&A
